Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Growing prevalence of N-acetylglutamate Synthase (NAGS) Syndrome and cancer cases
3.2.1.2 Rising incidences of metabolic diseases
3.2.1.3 Rise in awareness coupled with surging R&D activities by key i
3.2.2 Industry pitfalls & challenges
3.2.2.1 Adverse effects associated with carglumic acid medication
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Porter's analysis
3.6.1 Supplier power
3.6.2 Buyer power
3.6.3 Threat of new entrants
3.6.4 Threat of substitutes
3.6.5 Industry rivalry
3.7 PESTEL analysis
3.8 Future market trends
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Dosage From, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 Orally disintegrating tablets
5.3 Dispersible tablets
5.4 Other dosage forms
Chapter 6 Market Estimates and Forecast, By Distribution Channel, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 Hospital pharmacies
6.3 Retail pharmacies
6.4 Online pharmacies
Chapter 7 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 North America
7.2.1 U.S.
7.2.2 Canada
7.3 Europe
7.3.1 Germany
7.3.2 UK
7.3.3 France
7.3.4 Italy
7.3.5 Spain
7.3.6 Rest of Europe
7.4 Asia Pacific
7.4.1 China
7.4.2 Japan
7.4.3 India
7.4.4 Australia
7.4.5 South Korea
7.4.6 Rest of Asia Pacific
7.5 Latin America
7.5.1 Brazil
7.5.2 Mexico
7.5.3 Argentina
7.5.4 Rest of Latin America
7.6 Middle East and Africa
7.6.1 Saudi Arabia
7.6.2 South Africa
7.6.3 UAE
7.6.4 Rest of Middle East and Africa
Chapter 8 Company Profiles
8.1 Apothecon Pharmaceuticals Pvt. Ltd.
8.2 Biophore India Pharmaceuticals Pvt Ltd.
8.3 Dipharma Francis S.r.l.
8.4 Eton Pharmaceuticals
8.5 KAVYA PHARMA
8.6 MANUS AKTTEVA BIOPHARMA LLP
8.7 Merck KGaA
8.8 NOVITIUM PHARMA LLC
8.9 NURAY CHEMICALS
8.10 Recordati Rare Diseases Inc.
8.11 Suven Life Sciences Limited.
